文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗95例特应性皮炎患者的日常实践效果

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
PubMed 文献 · Br J Dermatol · 2019-10-16

这项观察性队列研究在荷兰两家大学医院前瞻性纳入95例接受度普利尤单抗治疗的成人特应性皮炎患者,评估日常实践中的疗效与安全性。眼症状和口面部(非眼部)单纯疱疹病毒再激活分别报告于62%和8%的患者,5例因副作用或无效停药。

要点

  • 度普利尤单抗在日常实践中对AD患者医生报告和患者报告结局均有临床相关改善。
  • 16周时38%患者达到IGA 0或1(清除/几乎清除),与III期临床试验主要结局一致。
  • 眼症状报告率62%,口面部非眼部HSV再激活8%,未见其他明显安全性问题。

核心结论

  • 度普利尤单抗在日常实践中对特应性皮炎患者医生报告结局和患者报告结局均有临床相关改善,与临床试验疗效数据一致。
  • 除频繁报告的眼症状和口面部(非眼部)HSV再激活外,未发现其他明显安全性问题。

研究设计与样本

  • 观察性队列研究,前瞻性纳入荷兰两家大学医院所有接受度普利尤单抗治疗的成人特应性皮炎患者,共95例。
  • 监测合并系统性免疫抑制治疗,分析随访≥12周的医生报告结局指标和患者报告结局指标,采用线性混合效应模型确定随访期间评分变化。

主要发现

  • 95例患者中,62例基线时使用系统性免疫抑制药,其中43例在度普利尤单抗治疗期间继续使用。
  • 患者报告结局指标估计均值下降41-66%。
  • 38%患者达到研究者全局评估0或1(清除/几乎清除)。
  • 5例因副作用或无效停止度普利尤单抗治疗;眼症状和口面部(非眼部)HSV再激活分别报告于62%和8%的患者。

关键数值与推荐

  • 患者报告结局指标估计均值下降41-66%。
  • 38%患者达到研究者全局评估0或1(清除/几乎清除)。
  • 眼症状报告于59/95例(62%),口面部(非眼部)HSV再激活报告于8/95例(8%)。

临床怎么用

  • 日常实践中度普利尤单抗可考虑用于成人中重度特应性皮炎,包括部分合并使用系统性免疫抑制药的患者。
  • 治疗期间需关注眼症状和口面部非眼部HSV再激活,但本队列随访至16周未见其他明显安全性信号。

局限性

  • 样本量95例,来自荷兰两家大学医院,随访至16周,外推需谨慎。
  • 为观察性队列研究,非随机对照,合并系统性免疫抑制药的影响未设对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab is the first biologic registered for the treatment of moderate-to-severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, there are limited daily practice data available for dupilumab, especially when it is combined with systemic immunosuppressants. OBJECTIVES: To evaluate dupilumab treatment in daily practice in patients with AD. METHODS: In this observational cohort study, we prospectively included all adult patients with AD who had been treated with dupilumab in two university hospitals in the Netherlands. Concomitant systemic immunosuppressive treatment was monitored. Physician-reported outcome measures and patient-reported outcome measures (PROMs) after ≥ 12 weeks of follow-up were analysed. We used a linear mixed-effects model to determine changes in scores during follow-up. RESULTS: Ninety-five patients were included. Of these, 62 patients were using systemic immunosuppressants at baseline; the use of systemic immunosuppressants was continued during dupilumab treatment in 43 patients. From baseline to 16 weeks of treatment, the estimated mean Eczema Area and Severity Index score (0-72) decreased from 18·6 [95% confidence interval (CI) 16·0-21·4)] to 7·3 (95% CI 5·4-10·0), and the estimated mean PROMs showed a decrease of 41-66%. Investigator's Global Assessment 0 or 1 (clear/almost clear) was reached in 38% of the patients. Five patients discontinued dupilumab treatment due to side-effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex virus (HSV) reactivation were reported in 62% and 8% of the patients, respectively. CONCLUSIONS: Dupilumab treatment in daily practice shows a clinically relevant improvement of physician-reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns. What's already known about this topic? Dupilumab has been shown to be an efficacious treatment for atopic dermatitis in several clinical trials. However, it is known that there may be considerable differences in patient characteristics and treatment responses between clinical trials and daily practice. What does this study add? This study presents the first experience with dupilumab treatment in 95 patients with atopic dermatitis in daily practice in two Dutch university hospitals. Less stringent inclusion and exclusion criteria and follow-up schedules, in contrast to those used in clinical trials, might better represent daily practice. Dupilumab treatment shows a clinically relevant improvement of physician- and patient-reported outcome measures; besides patient-reported eye symptoms (in 59 of 95 patients; 62%) and an apparent increase in orofacial (nonocular) herpes simplex virus reactivation (eight of 95 patients; 8%), there were no other safety concerns during follow-up up to 16 weeks of dupilumab treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. de Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2019. PMID: 31145810. doi:10.1111/bjd.18179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。